Sunday, December 7, 2025 12/7/2025

Informing optimal dosing of the future antimalarial, artemether-lumefantrine plus amodiaquine, in key neglected target populations of children with severe acute malnutrition and adults living with HIV

Award Number: K43TW012801
ORGANIZATION: FOGARTY INTERNATIONAL CENTER
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2024
PERIOD OF PERFORMANCE END DATE: 08/31/2029

Group Awards By:

View Award Description

Informing optimal dosing of the future antimalarial, artemether-lumefantrine plus amodiaquine, in key neglected target populations of children with severe acute malnutrition and adults living with HIV - PROJECT SUMMARY/ABSTRACT This award will allow Dr Clifford George Banda to characterise the pharmacokinetic and safety profiles of two long-acting artemisinin partner drugs, lumefantrine and amodiaquine and their active metabolites when administered as artemether-lumefantrine plus amodiaquine (ALAQ) in African young children with uncomplicated severe acute malnutrition as well as adults living with HIV and on dolutegravir-based antiretroviral therapy. Dr Banda, Malawi’s first medical specialist in Clinical Pharmacology and Therapeutics, will further his career development by;1) gaining skills in early phase clinical trial design and conduct in complex subpopulations; 2) consolidating skills in clinical translation of quantitative pharmacology (population pharmacokinetic-pharmacodynamic modelling) to inform dose optimisation of antimalarials in the two key target subgroups of children with severe acute malnutrition and adults living with HIV; and 3) strengthening his clinical and research leadership skills to allow transition into research career independence. In the proposed project work,he hypothesises that severe acute malnutrition is associated with reduced absorption and subsequent bioavailability of lumefantrine, amodiaquine and their active metabolites. Consequently, the attained concentrations would be insufficient to treat and prevent malaria recurrence. He will study the effect of uncomplicated severe acute malnutrition on lumefantrine and amodiaquine exposure. Furthermore, there are concerns about a potential reduction of dolutegravir exposure when amodiaquine is co-administered with dolutegravir-based antiretroviral therapy, Dr Banda will characterise the effect of ALAQ on dolutegravir overall exposure in adults living with HIV. This evidence is needed to inform the optimal dosing of the promising triple antimalarial combination, ALAQ, in these two subpopulations. It would support the World Health Organisation’s strategy for responding to antimalarial resistance in Africa by identifying innovative ways to combine and repurpose existing antimalarial therapies as a tool to delay antimalarial resistance while awaiting the development and licensing of novel non-artemisinin-based combination therapies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $108,804 )
2025	2025	KAMUZU UNIVERSITY OF HEALTH SCIENCES	1 MAHATMA GANDHI ROAD, MOUNT PLEASANT	BLANTYRE				MWI	International Research and Research Training	000	2	9/14/2025	NON-COMPETING CONTINUATION	$108,804
														Subtotal = $108,804

Issue Date FY: 2024 ( Subtotal = $108,916 )
2024	2024	KAMUZU UNIVERSITY OF HEALTH SCIENCES	1 MAHATMA GANDHI ROAD, MOUNT PLEASANT	BLANTYRE				MWI	International Research and Research Training	000	1	8/19/2024	NEW	$108,916
														Subtotal = $108,916

Grand Total All Awards = $217,720

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Informing optimal dosing of the future antimalarial, artemether-lumefantrine plus amodiaquine, in key neglected target populations of children with severe acute malnutrition and adults living with HIV

Award Number: K43TW012801

ORGANIZATION: FOGARTY INTERNATIONAL CENTER

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2024

PERIOD OF PERFORMANCE END DATE: 08/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer